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mice to evaluate the host immune responses towards the fusion
protein.
Results: A functionally active HA1 fusion protein consisting of
theHA1andAcmAprotein, linked together by a scFv linkerwas suc-
cessfully expressed andpuriﬁed. The fusionprotein has amolecular
mass of approximately 50kDa. Examination of the conditions for
binding of the fusion protein to L. lactis showed that a mixture of
20g of fusion protein with 108-109 L. lactis cells, GM17 as buffer
for binding and a binding incubation period of 2hours are most
suitable.
Conclusion: L. lactis surface displayingHA1 fusionprotein could
potentially develop as an alternative oral vaccine for preventing
inﬂuenza virus infection in humans.
http://dx.doi.org/10.1016/j.ijid.2014.03.1318
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Background: Leishmaniasis, aneglected tropical disease, preva-
lent in developing countries with 90% of them in Asia (Bangladesh,
India, and Nepal), Sudan, Ethiopia and Brazil. The technical chal-
lenges and the complexity in the immunity against the parasites
clearly contribute to the absence of vaccines. A major challenge in
humanvaccinedesign is toovercomevariation in immuneresponse
in a genetically heterogeneous population. This is largely deter-
mined by genetic heterogeneity in processing and presentation of
Ag to T cells, the outcome of which is dependent on binding of T
cell epitopes toHLA class I and class IImolecules that drive CD8 and
CD4T cell responses, respectively.
In silico screening for putative epitopes binding to DRB1
molecules can identify multiple epitopes per single parasite anti-
gen. Our quest here is to determinewhat actually occurs during the
course of a complex infection in vivo.
Methods & Materials: We are using in silico prediction tools
in an effort to understand more about the processes that direct
antigen selection and binding to different DRB1 molecules dur-
ing natural leishmanial infection. This will be done in concert with
analysis of naturally processed leishmanial peptides. A previously
conducted GWAS and further sequence based haplotyping on an
Indian population has indicated HLA class II as a major genetic risk
factor for visceral leishmaniasis(VL) and revealed DRB1*13/14 and
DRB1*15/16 as risk and protective alleles, respectively in VL. In a
preliminary study, we have obtained data on leishmanial epitopes
predicted to bind to DRB1*13/*14 risk vs DRB1*15/*16 protective
class II molecules using the in-silico predictive tool NetMHCIIpan
v2.1.
Results: Data for overlapping 9-mer epitopes has been gen-
erated for 27 known Leishmania antigens (antigens of diagnostic
value, vaccine candidates) and we have found peptides exclusively
binding to risk as well as protective group and also some differen-
tially binding peptides.
Conclusion: Functional validationof thesepeptideswill bedone
by measuring immune response against these antigens in individ-
uals carrying different allele group from endemic region in India.
Thiswill pave theway for appropriatevaccinecandidateswhichcan
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Background: Shingles causes considerable morbidity in older
persons. Zostavax, a vaccine against shingles, reduces the incidence
of shingles by 50% and the burden of illness by two-thirds. Little is
known about the factors that contribute to the patient’s intention
to get Zostavax
Methods & Materials: A two stage simple random sampling
process was undertaken to identify a random sample of GPs across
two urban areas in South Australia to identify the key beliefs about
shingles and its complications and the factors that may inﬂuence
the uptake of the Zostavax.
A random sample of each selected GP’s patients aged between
60 and 85 who had visited that GP at least once in the last 2 years
was selected and in interviewed by phone.
Principal component factor analysis with orthogonal (varimax)
rotation was used to reduce the number of patient characteristics
associated with vaccination intention in bivariate comparisons.
Survey weighted responses from GPs and patients were exam-
ined for their association with the patients’ likelihood to receive
the vaccine using the logistic regression
Results: Fifty GPs and 1330 patients were interviewed. About
half the GPs were very likely to recommend the Zoster vaccine.
82% of the patients knew of someone who had had shingles and
50% believed that it would have a big impact on their life. Just over
half would get Zostavax and 89% would, if their GP recommended
it.
The main predictor of getting Zostavax was if the patient’s GP
recommended it (OR 21.6 95% CI 13.8- 33.8). In factor analysis,
58 patient characteristics were reduced to 16 patient factors that
explained 73% of variance in patient intention to get Zostavax. After
adjustment for other predictors, GP recommendation remained the
strongest predictor of patient intention to get the Zoster vaccine.
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A number of GP factors interacted with patient predictors to get
Zostavax.
Conclusion: There is a high degree of awareness of the impact
of shingles and reasonable likelihood of vaccine uptake. GP recom-
mendation is likely to be the key inﬂuence on patients getting the
zoster vaccine.
Strategies to enhance GP recommendation of the Zostavax will
have a strong inﬂuence on Zostavax uptake
http://dx.doi.org/10.1016/j.ijid.2014.03.1320
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Background: In May 2013, the WHO sage announced a yel-
low fever vaccination policy change stating that revaccination of
healthy individuals every 10 years was no longer necessary. In our
opinion, this statementwas based on scarce research andwe there-
fore sought for a more solid base of evidence for this guideline.
The aim of this study is to assess antibody presence and yellow
fever (YF)-speciﬁc T cell responses in healthy individuals vacci-
nated more than 10 years ago.
Methods & Materials: From January 2012 to November 2013,
75 healthy individuals vaccinated more than 10 years ago and 30
individuals vaccinated less than 10 years ago were included in this
study. Virus neutralizing antibodies were studied using a Plaque
ReductionNeutralization Test. Thepresence andphenotypic proﬁle
of YF-speciﬁc CD8+T cells was characterised by tetramer staining.
YF-speciﬁc CD8+T cell responses were assessed after stimulation
with tetramer speciﬁc peptides.
Results: Neutralizing antibodies and YF speciﬁc CD8+T cells
were present in comparable percentages of long-term (up to
38 years after vaccination) and short-term vaccinees. In two
HLA A2+vaccinees vaccinated 12 and 15 years ago, (0.6-3.0%
of CD8+T cells) were identiﬁed and shown to have both
classical (CD45RAdimCD27+ ) and effector memory phenotypes
(CD45RAhiCD27). In one HLA B27+ individual vaccinated 28 years
ago, yellow fever speciﬁc T cells were identiﬁed after peptide stim-
ulation.
Conclusion: Antibodies were present up to 38 years following
vaccination. Functional YF-speciﬁc T cells with various phenotypes
were present up to 28 years after vaccination. The 17D yellow
fever vaccine induces a long term humoral and cellular immune
response, and our results provide a more solid base of evidence for
the WHO guideline change.
http://dx.doi.org/10.1016/j.ijid.2014.03.1321
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Background: Most meningococcal disease in Africa is caused
by serogroups A and W of N. meningitidis. Recently, new cases
of meningitis caused by N. meningitidis serogroup X have been
reported in countries from“meningitis belt”. Novaccines havebeen
developed against this serogroup. The aim of this work is to show
the different R&D strategies under evaluation at Finlay Institute
against the pathogen.
Methods & Materials: Experimental lots of outer membrane
vesicles (OMVx)were obtained bydeoxycholate extractionmethod
from N. meningitidis serogroup X BuFa 2/97 strain. Physico-
chemical characterization was carried out to determine the size,
morphology and the main antigens in vesicles. Secondly, capsu-
lar polysaccharide X (PsX) was obtained by phenol free process
and characterized by HPLC, HPAEC-PAD and other analytical tech-
niques. A combined formulation of OMVx plus PsX adsorbed to
aluminum hydroxide (OMVx/AL) was developed and evaluated in
mice models. Finally, conjugates of PsX to diphteria or tetanus tox-
oid were obtained. The antigen speciﬁc IgG responses induced by
these formulations to polysaccharides or OMVx were evaluated by
ELISA, and serum bactericidal assay (SBA).
Results: OMVx size was between 90-120nm and OpcA, PorA
and RmpM protein were identiﬁed. Lots from PsX were obtained
by high scale process (100 L). PsX size was estimated in 500g/mol L
and Kd in 0.5.OMVx/Al induced high speciﬁc anti-OMVx antibod-
ies response in sera with bactericidal activity. OMVx with PsX also
contributes to increase SBA in the group of mice immunized with
this formulation aswell as the induction of anti PsX antibodies. PsX
conjugates also induced high speciﬁc titers and SBA.
Conclusion: Puriﬁcation of capsular polysaccharide, combi-
nation of OMVx with the PsX as well as the formulation of
multivalent OMV vaccines or conjugates from different meningo-
coccal serogroups is the focus of our current work.
http://dx.doi.org/10.1016/j.ijid.2014.03.1322
